World Journal of Surgery

, Volume 42, Issue 8, pp 2428–2436 | Cite as

The Role of Surgery in Treating Resectable Limited Disease of Esophageal Neuroendocrine Carcinoma

  • Han-Yu Deng
  • Gang Li
  • Jun Luo
  • Xin-Rui Li
  • Guha Alai
  • Yi-Dan Lin
Original Scientific Report



Esophageal neuroendocrine carcinoma (NEC) is a rare malignant tumor. The role of surgery in resectable limited disease of esophageal NEC remains unclear. How to select a specific group of limited disease of esophageal NEC who might benefit from surgery remains to be answered.


Patients undergoing esophagectomy for resectable limited disease of esophageal NEC in our department from January 2007 to June 2015 were analyzed. TNM staging system was applied to describe those patients, and according to their different long-term prognosis after surgery, those patients were subgrouped into surgery response limited disease (SRLD) group and surgery non-response limited disease (SNRLD) group. Both univariate and multivariate analyses were applied to identify potential prognostic factors.


A total of 72 patients with resectable limited disease of esophageal NEC were identified for analysis. The median survival time of those patients was 21.5 months. There was no significant survival differences among stage I, stage IIA, and stage IIB patients, but all these patients had significantly longer survival than stage III patients. Therefore, stage I, stage IIA, and stage IIB patients were aggregated together as SRLD group, and stage III patients were aggregated as SNRLD group. SRLD patients obtained significantly longer survival than SNRLD patients in both univariate analysis and multivariate analysis. Moreover, adjuvant therapy could significantly benefit SRLD patients (P = 0.004) but could not benefit SNRLD patients (P = 0.136).


Different responses to surgery existed in resectable limited disease of esophageal NEC indicating the need of further subgrouping for those patients. The resectable limited disease of esophageal NEC could be further subgrouped into SRLD group and SNRLD group according to the TNM staging system.



This work was supported by National Natural Science Foundation of China [Nos. 81672291; 31071210] (to Yi-Dan Lin).

Compliance with ethical standards

Conflict of interests



  1. 1.
    Kloppel G (2011) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 18(Suppl 1):S1–16CrossRefPubMedGoogle Scholar
  2. 2.
    Rindi G (2011) Wiedenmann B Neuroendocrine neoplasms of the gut and pancreas: new insights Nature reviews. Endocrinology 8:54–64PubMedGoogle Scholar
  3. 3.
    Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72Google Scholar
  4. 4.
    Huang Q, Wu H, Nie L et al (2013) Primary high-grade neuroendocrine carcinoma of the esophagus: a clinicopathologic and immunohistochemical study of 42 resection cases. Am J Surg Pathol 37:467–483CrossRefPubMedGoogle Scholar
  5. 5.
    Nakajima Y, Zenda S, Minashi K et al (2012) Non-surgical approach to small cell carcinoma of the esophagus: does this rare disease have the same tumor behavior as SCLC? Int J Clin Oncol 17:610–615CrossRefPubMedGoogle Scholar
  6. 6.
    Diagnosis Stahel RA (1991) staging, and prognostic factors of small cell lung cancer. Curr Opin Oncol 3:306–311CrossRefGoogle Scholar
  7. 7.
    Wang SY, Mao WM, Du XH et al (2013) The 2002 AJCC TNM classification is a better predictor of primary small cell esophageal carcinoma outcome than the VALSG staging system. Chin J Cancer 32:342–352PubMedPubMedCentralGoogle Scholar
  8. 8.
    Micke P, Faldum A, Metz T et al (2002) Staging small cell lung cancer: veterans administration lung study group versus international association for the study of lung cancer–what limits limited disease? Lung Cancer (Amsterdam, Netherlands) 37:271–276CrossRefGoogle Scholar
  9. 9.
    Situ D, Lin Y, Long H et al (2013) Surgical treatment for limited-stage primary small cell cancer of the esophagus. Ann Thorac Surg 95:1057–1062Google Scholar
  10. 10.
    Hou X, Wei JC, Wu JX et al (2013) Multidisciplinary modalities achieve encouraging long-term survival in resectable limited-disease esophageal small cell carcinoma. PloS One 8:e69259CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Chen SB, Yang JS, Yang WP et al (2011) Treatment and prognosis of limited disease primary small cell carcinoma of esophagus. Dis Esophagus 24:114–119Google Scholar
  12. 12.
    Meng MB, Zaorsky NG, Jiang C et al (2013) Radiotherapy and chemotherapy are associated with improved outcomes over surgery and chemotherapy in the management of limited-stage small cell esophageal carcinoma. Radiother Oncol 106:317–322Google Scholar
  13. 13.
    Chen WW, Wang F, Chen S et al (2014) Detailed analysis of prognostic factors in primary esophageal small cell carcinoma. Ann Thorac Surg 97:1975–1981Google Scholar
  14. 14.
    Jatoi A, Miller RC (2008) Should we recommend surgery to patients with limited small cell carcinoma of the esophagus? J Thorac Oncol 3:1373–1376CrossRefPubMedGoogle Scholar
  15. 15.
    Maru DM, Khurana H, Rashid A et al (2008) Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol 32:1404–1411Google Scholar
  16. 16.
    Tanaka T, Matono S, Nagano T et al (2010) Surgical management for small cell carcinoma of the esophagus. Dis Esophagus 23:502–505CrossRefPubMedGoogle Scholar
  17. 17.
    Chen SB, Yang JS, Yang WP et al (2011) Treatment and prognosis of limited disease primary small cell carcinoma of esophagus. Dis Esophagus 24:114–119CrossRefPubMedGoogle Scholar
  18. 18.
    Yau KK, Siu WT, Wong DC et al (2007) Non-operative management of small cell carcinoma of esophagus. Dis Esophagus 20:487–490CrossRefPubMedGoogle Scholar
  19. 19.
    Lu XJ, Luo JD, Ling Y et al (2013) Management of small cell carcinoma of esophagus in China. J Gastrointest Surg 17:1181–1187Google Scholar
  20. 20.
    Deng HY, Ni PZ, Wang YC et al (2016) Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection. J Thorac Dis 8:1250–1256CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Lv J, Liang J, Wang J et al (2008) Primary small cell carcinoma of the esophagus. J Thorac Oncol 3:1460–1465Google Scholar
  22. 22.
    de Hoyos A, DeCamp MM (2014) Surgery for small cell lung cancer. Thorac Surg Clin 24:399–409Google Scholar
  23. 23.
    Hudson E, Powell J, Mukherjee S et al (2007) Small cell oesophageal carcinoma: an institutional experience and review of the literature. Br J Cancer 96:708–711Google Scholar
  24. 24.
    Zou B, Li T, Zhou Q et al (2016) Adjuvant therapeutic modalities in primary small cell carcinoma of esophagus patients: a retrospective cohort study of multicenter clinical outcomes. Medicine 95:e3507CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2018

Authors and Affiliations

  • Han-Yu Deng
    • 1
    • 2
  • Gang Li
    • 1
  • Jun Luo
    • 1
  • Xin-Rui Li
    • 1
  • Guha Alai
    • 1
  • Yi-Dan Lin
    • 1
  1. 1.Department of Thoracic Surgery, West China HospitalSichuan UniversityChengduChina
  2. 2.Lung Cancer Center, West China HospitalSichuan UniversityChengduChina

Personalised recommendations